Siah Kewin T H, Wong Reuben K, Whitehead William E
Dr Siah is an associate consultant in the Division of Gastroenterology and Hepatology at the University Medicine Cluster at National University Hospital and Yong Loo Lin School of Medicine at the National University of Singapore in Kent Ridge, Singapore. Dr Wong is an adjunct associate professor of medicine at Yong Loo Lin School of Medicine at the National University of Singapore. Dr Whitehead is a professor of medicine, adjunct professor of obstetrics and gynecology, and director of the Center for Functional Gastrointestinal and Motility Disorders at the University of North Carolina at Chapel Hill in Chapel Hill, North Carolina.
Gastroenterol Hepatol (N Y). 2016 Mar;12(3):171-8.
Rome III diagnostic criteria separate patients with idiopathic chronic constipation into mutually exclusive categories of constipation-predominant irritable bowel syndrome (IBS-C) or functional constipation (FC). However, several experts think that these conditions are not different disorders, but parts of a continuum. To shed light on this issue, we examined studies that compared IBS-C with FC with respect to symptoms, pathophysiologic mechanisms, and treatment response. When the Rome III requirement that patients meeting criteria for IBS cannot also be given a diagnosis of FC is suspended, most patients meet criteria for both, and, contrary to expectation, IBS-C patients have more symptoms of constipation than patients with FC. No symptoms reliably separate IBS-C from FC. Physiologic tests are not reliably associated with diagnosis, but visceral pain hypersensitivity tends to be more strongly associated with IBS-C than with FC, and delayed colonic transit tends to be more common in FC. Although some treatments are effective for both IBS-C and FC, such as prosecretory agents, other treatments are specific to IBS-C (eg, antidepressants, antispasmodics, cognitive behavior therapy) or FC (eg, prucalopride, biofeedback). Future studies should permit IBS-C and FC diagnoses to overlap. Physiologic tests comparing these disorders should include visceral pain sensitivity, colonic transit time, time to evacuate a water-filled balloon, and anal pressures or electromyographic activity from the anal canal. To date, differential responses to treatment provide the strongest evidence that IBS-C and FC may be different disorders, rather than parts of a spectrum.
罗马Ⅲ诊断标准将特发性慢性便秘患者分为相互排斥的便秘型肠易激综合征(IBS-C)或功能性便秘(FC)类别。然而,一些专家认为这些病症并非不同的疾病,而是一个连续统一体的组成部分。为阐明这一问题,我们研究了比较IBS-C与FC在症状、病理生理机制及治疗反应方面的研究。当暂停罗马Ⅲ标准中关于符合IBS标准的患者不能同时诊断为FC这一要求时,大多数患者同时符合两者的标准,并且与预期相反,IBS-C患者的便秘症状比FC患者更多。没有症状能可靠地区分IBS-C和FC。生理测试与诊断并无可靠关联,但内脏疼痛超敏反应与IBS-C的关联往往比与FC更强,而结肠传输延迟在FC中往往更常见。尽管一些治疗方法对IBS-C和FC均有效,如促分泌剂,但其他治疗方法则分别针对IBS-C(如抗抑郁药、解痉药、认知行为疗法)或FC(如普芦卡必利、生物反馈)。未来的研究应允许IBS-C和FC的诊断相互重叠。比较这些病症的生理测试应包括内脏疼痛敏感性、结肠传输时间、排出充水球囊的时间以及肛管压力或肌电图活动。迄今为止,治疗反应的差异提供了最有力的证据,表明IBS-C和FC可能是不同的疾病,而非一个谱系的组成部分。